Reproduction and Genetics Center, Dalian Municipal Women and Children's Medical Center, Dalian, Liaoning, People's Republic of China.
Laboratory Department, Dalian Municipal Women and Children's Medical Center, Dalian, Liaoning, People's Republic of China.
Gynecol Endocrinol. 2022 Apr;38(4):318-323. doi: 10.1080/09513590.2022.2034147. Epub 2022 Mar 14.
extract (EGb) has been widely applied in the treatment of cerebrovascular and neurological diseases. However, the effect of EGb761 on ovarian hyperstimulation syndrome (OHSS), a vascular disorder and life-threatening complication of in vitro fertilization and intracytoplasmic sperm injection therapy (IVF/ICSI), has not been evaluated.
Forty female Wistar rats aged 22-days old (D22) were divided into eight groups: Control rats received intraperitoneal injection of saline for five consecutive days (D22-D26); OHSS model group received 10 IU equine chorionic gonadotropin (eCG) for four consecutive days (D22-D25) and 30 IU of human chorionic gonadotropin (hCG) on the 5th day (D26); Prophylactic treatment group received three doses of EGb761 (50, 100, and 200 mg/kg/day) 1 h before injection of eCG (hCG) for seven consecutive days; Therapeutic treatment group received three doses of EGb761 (50, 100, and 200 mg/kg/day) 48 h after injection of eCG (hCG) for seven consecutive days.
All three doses of EGb761 therapeutic medication significantly reduced ovarian mass index of OHSS model rats ( ≤ .01). Furthermore, therapeutic treatment group exhibited improved vascular permeability, decreased estradiol and progesterone levels, lower corpus luteum, and higher follicle numbers compared with the OHSS model. Elevated protein expression of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) in both ovary and kidney of the OHSS model was restrained by EGb761 therapeutic treatment.
EGb761 therapeutic medication decreases vascular permeability in OHSS rat model by inhibiting VEGF and VEGFR expression, which may contribute to the treatment of OHSS.
银杏叶提取物（EGb）已广泛应用于治疗脑血管和神经疾病。然而，EGb761 对卵巢过度刺激综合征（OHSS）的影响尚未得到评估，OHSS 是体外受精和胞浆内精子注射治疗（IVF/ICSI）的一种血管疾病和危及生命的并发症。
40 只 22 天大的 Wistar 雌性大鼠（D22）分为 8 组：对照组大鼠连续 5 天腹腔注射生理盐水（D22-D26）；OHSS 模型组连续 4 天注射 10IU 马绒毛膜促性腺激素（eCG）（D22-D25），第 5 天注射 30IU 人绒毛膜促性腺激素（hCG）（D26）；预防治疗组连续 7 天，在注射 eCG（hCG）前 1 小时分别给予 EGb761（50、100 和 200mg/kg/天）3 个剂量；治疗治疗组连续 7 天，在注射 eCG（hCG）后 48 小时给予 EGb761（50、100 和 200mg/kg/天）3 个剂量。
EGb761 治疗药物的三个剂量均显著降低 OHSS 模型大鼠的卵巢质量指数（≤.01）。此外，与 OHSS 模型相比，治疗治疗组显示血管通透性改善、雌二醇和孕酮水平降低、黄体减少、卵泡数量增加。EGb761 治疗可抑制 OHSS 模型卵巢和肾脏中血管内皮生长因子（VEGF）和血管内皮生长因子受体（VEGFR）的蛋白表达。
EGb761 治疗药物通过抑制 VEGF 和 VEGFR 的表达降低 OHSS 大鼠模型的血管通透性，可能有助于治疗 OHSS。
